Cyclin-Dependent Kinase Inhibitor p16
"Cyclin-Dependent Kinase Inhibitor p16" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A product of the p16 tumor suppressor gene (GENES, P16). It is also called INK4 or INK4A because it is the prototype member of the INK4 CYCLIN-DEPENDENT KINASE INHIBITORS. This protein is produced from the alpha mRNA transcript of the p16 gene. The other gene product, produced from the alternatively spliced beta transcript, is TUMOR SUPPRESSOR PROTEIN P14ARF. Both p16 gene products have tumor suppressor functions.
| Descriptor ID |
D019941
|
| MeSH Number(s) |
D12.644.360.225.200 D12.776.167.187.200 D12.776.476.225.200 D12.776.624.776.355.200
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p16- Cyclin-Dependent Kinase Inhibitor p16
- Cyclin Dependent Kinase Inhibitor p16
- CDKN2 Protein
- CDKN2A Protein
- MTS1 Protein
- p16INK4 Protein
- p16(INK4A)
- INK4A Protein
- Protein, INK4A
- Cyclin-Dependent Kinase Inhibitor-2A
- Cyclin Dependent Kinase Inhibitor 2A
- Multiple Tumor Suppressor-1
- Multiple Tumor Suppressor 1
- Cdk4-Associated Protein p16
- Cdk4 Associated Protein p16
- p16INK4A Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p16".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p16".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p16" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p16" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 2 | 1 | 3 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 2 | 4 |
| 2014 | 4 | 2 | 6 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 4 | 2 | 6 |
| 2019 | 3 | 3 | 6 |
| 2021 | 2 | 3 | 5 |
| 2022 | 2 | 2 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p16" by people in Profiles.
-
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct; 8:e2400477.
-
Circulating tumor DNA predicts venous thromboembolism in patients with cancers. J Thromb Haemost. 2025 Jan; 23(1):139-148.
-
The DNA methylome of pediatric brain tumors appears shaped by structural variation and predicts survival. Nat Commun. 2024 Aug 08; 15(1):6775.
-
TERT activation targets DNA methylation and multiple aging hallmarks. Cell. 2024 Jul 25; 187(15):4030-4042.e13.
-
Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas. Neuro Oncol. 2024 06 03; 26(6):1042-1051.
-
Dietary Folate and Cofactors Accelerate Age-dependent p16 Epimutation to Promote Intestinal Tumorigenesis. Cancer Res Commun. 2024 01 19; 4(1):164-169.
-
Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma. Acta Neuropathol. 2023 04; 145(4):501-503.
-
The impact of senescence on muscle wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2023 02; 14(1):126-141.
-
Bmi1 suppresses protein synthesis and promotes proteostasis in hematopoietic stem cells. Genes Dev. 2022 08 01; 36(15-16):887-900.
-
p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade. Cancer Res. 2022 03 01; 82(5):916-928.